| |
dNP(n=66) |
vNP(n=20) |
Others(n=4) |
| Age (years) |
59+9* |
66+8* |
52-6 |
| Sex (% fem) |
48% |
55% |
50% |
| Caucasian (%) |
100% |
100% |
100% |
| HbA1c (%) |
7.8+1.2 |
7.9+1.2 |
7.6+0.9 |
| Antidiabetic therapy (n/%) |
| Sulfonylurea oral |
12 (18%) |
4 (20%) |
0 |
| Insulin conventional |
24 (36%) |
10 (50%) |
0 |
| Insulin intensified |
24 (36%) |
6 (30%) |
0 |
| Diet alone |
6 (10%) |
2 (10%) |
4 (100%) |
| Serum Creatinine (mg/dl) |
6.8 ± 1.2 |
7.2 ± 1.4 |
6.2 ± 1.2 |
| Cr-clearance (ml/min/1.73m2) |
12 (4-16) |
8 (2-12) |
7 (6-14) |
| Hypertention (n/%) |
62 (93%) |
19 (95%) |
1 (25%) |
| ACE inhibitors (/%) |
41 (62%) |
12 (60%) |
0 |
| Cholestderol (mgl) |
146 ± 26 |
142 ± 29 |
165 ± 32 |
| Trglycerides (mg/dl) |
152 ± 30 |
148 ± 38 |
145 ± 34 |
| Smoking (n/%) |
24 (36%) |
7 (35%) |
1 (25%) |
*p>0.05 |
